Skip to content
Peptide research

Palmitoyl Dipeptide-6

Also known as Pal-Lys-Val ยท Syn-Tacks
Category
Skin & Cosmetic
Administration routes
Topical
Regulatory status
Cosmetic ingredient

A palmitoylated dipeptide marketed in anti-aging serums to firm skin, smooth crow's feet, and rebuild the dermal-epidermal junction. Evidence is almost entirely mechanistic and in vitro; human proof of real wrinkle or firmness improvement is speculative. The palmitoyl chain aids penetration, not efficacy. Safety data are limited, and excipient allergy is a real, moderate risk. It is a cosmetic ingredient, not an FDA-approved drug, subject to FDA cosmetic requirements.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Palmitoyl Dipeptide-6 is a synthetic two-amino-acid peptide attached to a fatty acid chain, designed to strengthen the junction where the outer layer of skin (epidermis) connects to the deeper layer (dermis). This junction weakens with age, leading to sagging, loss of firmness, and wrinkles. The peptide is the key ingredient in the cosmetic complex SYN-TACKS, developed by dsm-firmenich (formerly DSM), where it works alongside a partner peptide (Palmitoyl Dipeptide-5) to rebuild the anchoring proteins that hold skin layers together.

How it works in the body

Contains a palmitoyl chain attached to a dipeptide that activates fibroblast growth. It stimulates the production of key extracellular matrix proteins โ€” dermal-epidermal junction proteins โ€” collagen types IV, VII, and XVII, laminin V, and integrin โ€” by fibroblasts in the dermis, improving skin structure and hydration.

Research overview

Palmitoyl Dipeptide-6 works by signaling skin cells to produce more of the specific structural proteins โ€” laminin V, collagen types IV, VII, and XVII, and integrin beta-4 โ€” that anchor the epidermis to the dermis. Think of these proteins as the rivets holding two layers of fabric together; as they deteriorate with age, the layers separate and skin loses its firmness. In manufacturer-sponsored studies, the SYN-TACKS complex (at 1% concentration over 56-84 days) improved skin firmness, compactness, and reduced wrinkles. A different complex of biotinylated and ascorbyl-linked peptides showed wrinkle improvement in 22 volunteers after two weeks. However, most efficacy data comes from the manufacturer rather than independent peer-reviewed trials, and there are no registered clinical studies specifically for this peptide. CIR's broad palmitoyl-oligopeptide assessment was deferred for regrouping, without establishing this ingredient's safety.

Who researches Palmitoyl Dipeptide-6?

Commonly researched by

  • People researching skin health and rejuvenation

    Studied for collagen synthesis, skin repair, or anti-aging skin effects.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High ยท Medium ยท Low ยท Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High ยท Moderate ยท Low ยท Theoretical
Interactions
= direction with this peptide: Protective / Synergistic ยท Caution ยท Neutral

Risk summary(3)

Rated by level of concern

  • Contact dermatitis or skin irritation (theoretical)

    Low

    Absence of indexed case reports; general cosmetic-peptide safety experience (no ingredient-specific safety study located)

  • Limited long-term safety data

    Low

    No indexed long-term safety or toxicology publication identified for palmitoyl dipeptide-6

  • Allergic reaction to formulation excipients

    Moderate

    Established dermatology patch-test literature on leave-on cosmetic vehicles (fragrance mix, preservatives); general reference, not ingredient-specific

Interaction summary(8)

Rated by direction with this peptide

  • Topical retinoids (tretinoin, adapalene, retinol)

    CautionLow

    Concurrent use is common and mechanistically complementary for matrix remodeling, but retinoid-induced barrier disruption and irritation can be additive with any leave-on serum, so stagger application or introduce sequentially in sensitive skin. The caution derives entirely from retinoid tolerability, not from any property of the peptide.

    Retinoid irritation is well established clinically; no interaction study exists for this peptide

  • Alpha/beta hydroxy acid exfoliants (glycolic, lactic, salicylic acid)

    CautionTheoretical

    Low-pH exfoliants may increase transepidermal penetration of co-applied peptides and can add to cumulative irritation, and acidic pH may destabilize peptide actives in the same layer. Both effects are formulation-chemistry inference, not measured for this molecule.

    Formulation-chemistry principle; no published interaction data

  • L-ascorbic acid (topical vitamin C)

    SynergisticLow

    Ascorbate is a required cofactor for prolyl and lysyl hydroxylases in collagen maturation, and a published palmitoylated-peptide/ascorbate conjugate (palmitoyl-KVK-L-ascorbic acid) increased type I collagen and reduced melanin, making co-use mechanistically coherent. This is coherence rather than demonstrated synergy: no study has co-applied vitamin C with palmitoyl dipeptide-6, and the conjugate's effects may be driven by the ascorbyl moiety alone.

    PMID 28303328; synergy with dipeptide-6 specifically is inferred, not tested

  • Broad-spectrum sunscreen / photoprotection

    ProtectiveLow

    UV exposure drives MMP-mediated degradation of the same basement-membrane and dermal matrix proteins this peptide is claimed to stimulate, so photoprotection is the dominant variable in any antiaging regimen and would protect any peptide-driven gain that exists.

    Established photoaging and MMP literature (general)

  • Topical corticosteroids (chronic facial use)

    CautionModerate

    Sustained topical steroid use suppresses fibroblast collagen synthesis and causes dermal atrophy, which would oppose any matrix-building effect at the application site. The Moderate rating reflects the well-documented harm of chronic facial steroid use itself, not a demonstrated interaction with this peptide - whose benefit is unproven and therefore cannot be shown to be negated.

    Well-established corticosteroid-induced skin atrophy literature (general)

  • Benzoyl peroxide

    CautionTheoretical

    As a strong oxidizer, benzoyl peroxide can degrade peptide and ascorbate actives when layered simultaneously; separate to different times of day rather than mixing in one layer. Stability inference only - not measured for this peptide, and the consequence is loss of efficacy rather than harm.

    Formulation-stability principle; no published data for this peptide

  • Barrier-compromising procedures (microneedling, ablative laser, chemical peels, post-procedure skin)

    CautionModerate

    These procedures bypass the stratum corneum and can convert a negligible-absorption cosmetic into meaningful dermal exposure of a molecule with no injectable or intradermal safety data, and raise irritant and foreign-body/granulomatous risk from excipients not intended for broken skin. Rated Moderate because post-procedure granulomatous reactions to topical cosmetics applied to compromised skin are a documented phenomenon in dermatology, even though nothing product-specific exists here.

    General post-procedure topical-safety guidance and case literature on cosmetics applied to compromised skin; no product-specific data

  • Systemic medications (oral drugs of any class)

    NeutralLow

    Topical application of a lipidated dipeptide is expected to yield negligible systemic absorption, with no known CYP or transporter activity, so clinically meaningful systemic drug interactions are not expected. This is pharmacokinetic inference from the molecule's class and size, not a measured absorption study.

    Pharmacokinetic inference; no absorption or systemic-exposure data published for this peptide

Known risks(3)

  • Contact dermatitis or skin irritation (theoretical)

    Very Low

    The cited CIR literature review does not establish ingredient-specific irritation or sensitization safety. The EWG hazard score is 1/10. However, as with any topical peptide, rare individual sensitivity is possible. The palmitoyl moiety enhances skin penetration, which could theoretically increase reactivity in extremely sensitive individuals.

  • Limited long-term safety data

    Low (Data Gap)

    Long-term studies (>1 year) on repeated topical application of Palmitoyl Dipeptide-6 specifically have not been published. The cited CIR review does not provide a completed safety assessment of Palmitoyl Dipeptide-6. Given the low concentrations used in cosmetics (<0.01% active peptide), systemic exposure risk is considered negligible.

  • Allergic reaction to formulation excipients

    Low

    The peptide itself has low allergenic potential, but finished products containing Palmitoyl Dipeptide-6 include other ingredients (fragrances, preservatives, botanical extracts) that may cause allergic reactions in susceptible individuals. Risk is attributable to the formulation, not the peptide specifically.

Drug interactions(4)

  • Topical retinoids (tretinoin, adapalene, retinol)

    No direct pharmacological interaction. However, retinoids thin the stratum corneum and increase skin permeability, which could theoretically enhance peptide penetration and potentially increase irritation in sensitive individuals. Both ingredients target collagen pathways and may have complementary effects. Allow retinoid to absorb fully before applying peptide products.

  • Topical acids (AHAs, BHAs, vitamin C at low pH)

    Acidic environments (pH <3.5) may denature or hydrolyze the peptide bond, reducing efficacy. Glycolic acid, salicylic acid, and L-ascorbic acid at low pH should be applied at different times of day or allowed to fully absorb and neutralize on skin before peptide application. Peptides are generally most stable at pH 5-7.

  • Other topical peptides (Matrixyl, Argireline, copper peptides)

    No known adverse interactions. Palmitoyl Dipeptide-6 is commonly formulated alongside other cosmetic peptides. Copper peptides (GHK-Cu) may theoretically interact with peptide bonds but this is not clinically significant at cosmetic concentrations. Layering multiple peptide products is generally considered safe.

  • Topical benzoyl peroxide

    Benzoyl peroxide is a strong oxidizer that can degrade peptide structures on contact. Do not apply simultaneously. Use at different times of day to preserve peptide efficacy.

Research & benefits

Evidence base

Evidence Level
Preclinical
Total Studies
6
Human Studies
150

Clinical evidence for Palmitoyl Dipeptide-6 is limited to manufacturer-sponsored cosmetic evaluations and small studies of other peptides. No independent, large-scale, randomized, placebo-controlled clinical trials have been published specifically for this ingredient. The DSM SYN-TACKS clinical program tested the peptide combination at 1% concentration over 56-84 days and reported improvements in skin compactness, wrinkle reduction, and tonicity, but detailed methodology, sample sizes, and statistics are available only in proprietary brochures rather than peer-reviewed publications. Published studies of the distinct palmitoyl-KVK-L-ascorbic acid conjugate (PMID 28303328) and of a different complex of biotinylated and ascorbyl-linked peptides (PMID 31861912) reported wrinkle improvement in small human trials (n=22-32), but they tested different ingredients. CIR deferred the broad 2013 assessment for regrouping; it did not establish this ingredient's safety.

Researched for(5)

Rated by confidence in the evidence

  • Stimulation of dermal-epidermal junction (DEJ) structural proteins (Collagen IV, VII, XVII, Laminin V, Integrin beta-4)

    Speculative

    A related lipopeptide raised laminin and collagen IV/XVII in skin cells; this molecule is untested.

    PMID 36043531 (Palmitoyl-RGD promotes expression of dermal-epidermal junction components in HaCaT cells, Mol Med Rep 2022 - analog only); no indexed clinical or in-vitro study identified for palmitoyl dipeptide-6 itself

  • Reduction in fine lines and wrinkles, particularly periorbital crow's feet

    Speculative

    No published trials; wrinkle claims come from unpublished, multi-ingredient manufacturer testing.

    No PubMed or ClinicalTrials.gov record identified for palmitoyl dipeptide-6 wrinkle trials

  • Improved skin firmness, compactness, and elasticity

    Speculative

    Inferred from proposed matrix protein effects; no human elasticity or firmness data exist.

    Mechanistic inference only; no indexed human elasticity data for palmitoyl dipeptide-6

  • Enhanced skin penetration and stability via palmitoyl lipidation

    Low

    In related peptides, lipidation improved stability and skin penetration versus unmodified forms; untested here.

    PMID 25143811 (Dermal stability and in vitro skin permeation of KTTKS and palmitoyl-KTTKS, Biomol Ther 2014); PMID 39783908 (ionic-liquid self-assembled nanomicelles developed to enhance transdermal delivery of palmitoyl pentapeptide-4, Adv Sci 2025; supports the need for solubilizing delivery, not a solubility-limit measurement per se)

  • Collagen I synthesis stimulation and anti-pigmentation effects (related Pal-KVK sequence)

    Speculative

    Single study on a different ascorbic-acid conjugate showed collagen and pigment effects, not this peptide.

    PMID 28303328 (Effects of palmitoyl-KVK-L-ascorbic acid on skin wrinkles and pigmentation, Arch Dermatol Res 2017; different molecule)

Benefits(5)

  • Stimulation of dermal-epidermal junction (DEJ) structural proteins (Collagen IV, VII, XVII, Laminin V, Integrin beta-4)

    DSM/dsm-firmenich SYN-TACKS in vitro data; Jeong et al. 2019 (PMID 31861912) demonstrated peptide-induced upregulation of collagen XVII, laminin, and nidogen in keratinocytes

  • Reduction in fine lines and wrinkles, particularly periorbital crow's feet

    DSM SYN-TACKS clinical evaluation (56-84 days, 1% concentration); Byrne et al. 2010 (PMID 20618556) showed triple peptide complex targeting collagen IV significantly reduced wrinkle depth in 22 volunteers over 4-12 weeks

  • Improved skin firmness, compactness, and elasticity

    DSM SYN-TACKS clinical data; Sanz et al. 2016 (PMID 26424007) demonstrated significant increase in dermal density and skin elasticity with palmitoyl peptide-containing serum in 32 women over 28 days

  • Enhanced skin penetration and stability via palmitoyl lipidation

    Xiong et al. 2026 (PMID 41344485) demonstrated Pal-KVK self-assembled nanostructures achieved up to 94% transdermal rate with sustained release and excellent biocompatibility

  • Collagen I synthesis stimulation and anti-pigmentation effects (related Pal-KVK sequence)

    Kim et al. 2017 (PMID 28303328) showed palmitoyl-KVK-L-ascorbic acid increased type I collagen expression dose-dependently and reduced melanin content by ~20% in vitro; clinical improvement in skin roughness at 12 weeks

Key studies(5)

  1. Jeong S, Yoon S, Kim S, Jung J, Kor M, Shin K, Lim C, Han HS, Lee H, Park KY, Kim J, Chung HJ, Kim HJ

    International Journal of Molecular Sciences

    2019

    Peptide complex stimulated collagen XVII, laminin, and nidogen expression in cultured human keratinocytes. Ex vivo topical application on excised human skin significantly increased dermal collagen and DEJ protein expression. Clinical study in 22 Asian women (age >40) showed significant wrinkle improvement at all five measured facial sites after just 2 weeks of application.

  2. Effects of palmitoyl-KVK-L-ascorbic acid on skin wrinkles and pigmentation

    In vitro + Clinical trialNot specified (clinical arm)12 weeks

    Kim HM, An HS, Bae JS, Kim JY, Choi CH, Kim JY, Lim JH, Choi JH, Song H, Moon SH, Park YJ, Chang SJ, Choi SY

    Archives of Dermatological Research

    2017

    The distinct palmitoyl-KVK-L-ascorbic acid conjugate increased type I collagen expression dose-dependently in dermal fibroblasts (0.1-4 ug/mL). Reduced melanin content by ~20% in B16F1 cells. Clinical application of Pal-KVK-ascorbic acid cream improved skin roughness at 12 weeks and skin lightness at 8 weeks vs placebo.

  3. Synergistic action of a triple peptide complex on an essential extra-cellular matrix protein exhibits significant anti-aging benefits

    In vitro + Double-blind RCT + Monadic clinical studyn=22 (Study 1, RCT); additional monadic study4 weeks (Study 1); 12 weeks (Study 2)

    Byrne AJ, Al-Bader T, Kerrigan D, Hickey S, Laloeuf A, Rawlings AV

    Journal of Cosmetic Dermatology

    2010

    Triple peptide complex stimulated collagen IV production in aged fibroblasts (1.4 vs 0.32 ng/ng total protein, >4-fold increase). In a double-blind, placebo-controlled 4-week study on 22 volunteers with periorbital wrinkles, significant wrinkle reduction was measured by profilometry. A 12-week monadic study confirmed wrinkle score improvements, demonstrating DEJ-targeting peptides' clinical efficacy.

  4. Lipidated peptide nanostructures for stabilizing hydrogels with sustained skincare bioactivity

    In vitro / Preclinical / Consumer evaluationConsumer panel (size not specified)12 hours sustained release evaluation

    Xiong Y, Wu M, Hou X, Yuchun Han, Chen H, Tang H, Meiwen Cao

    Journal of Controlled Release

    2026

    Pal-KVK, a different palmitoylated tripeptide, formed helical ribbon self-assembled nanostructures enabling sustained skincare ingredient release. Achieved up to 94% transdermal penetration rate. Pal-KVK/gelatin composite hydrogel mask demonstrated excellent anti-wrinkle and moisturizing effects in consumer dermatological evaluations. Confirmed biocompatibility via cellular toxicity assays.

  5. Sanz MT, Campos C, Milani M, Foyaca M, Lamy A, Kurdian K, Trullas C

    Journal of Cosmetic Dermatology

    2016

    Serum containing palmitoyl tripeptide-38 (a related signal peptide) plus apple stem cell extract showed anti-wrinkle effect in 71% of treated women, with visible results in 68% as early as 7 days. Significant increase in dermal density and skin elasticity observed. In vitro: significant reduction in mitochondrial ROS and improvement in cellular metabolic functions in senescent fibroblasts.

Regulation & availability

Why researchers look at it

Targets a structural weak point most anti-aging ingredients ignore: the dermal-epidermal junction, where skin layers anchor together and which deteriorates with age. Manufacturer studies of SYN-TACKS reported firmness and wrinkle improvements. The separate 22-person study reporting improvement after two weeks tested a different peptide complex. If independent research confirms the junction-repair mechanism, this could fill a gap that collagen-boosting peptides alone do not address.

Estimated cost
$20-60/mo in OTC serums
FDA status
Not FDA-approved as a drug. Palmitoyl Dipeptide-6 is a cosmetic ingredient marketed for topical cosmetic use; cosmetics remain FDA-regulated and generally do not require premarket approval, except for color additives. A product that claims to treat a condition or change how the body works is regulated as a drug. Manufacturers must substantiate safety and comply with applicable labeling and MoCRA requirements. The cited CIR review does not establish this ingredient's safety. CosIng inclusion, if verified for the exact ingredient, would not constitute EU approval.
WADA status
Not expressly named in the 2026 List. Cosmetic use does not provide a blanket exemption; S0 may cover unapproved pharmacological substances. Ingredient-specific clearance was not established.
Prescribability
No -- Not a Prescription Drug. Palmitoyl Dipeptide-6 is a cosmetic ingredient, not a pharmaceutical. It is not prescribed by physicians and does not require a prescription. It is available over the counter in anti-aging skincare formulations (serums, creams, eye creams) from various cosmetic brands.
Availability
Palmitoyl Dipeptide-6 is widely available as a cosmetic ingredient, not a pharmaceutical. Consumers can access it through finished skincare products from brands including Peter Thomas Roth (Un-Wrinkle series), Mad Hippie (Face Cream), Eva Naturals (Hyaluronic Acid Serum), Plexaderm, Jafra, and others -- typically in anti-aging serums, eye creams, and moisturizers. Commercial formulations contain up to 1% (v/v). No prescription, medical consultation, or clinical setting is required for access.

International status

  • EU

    Available OTC in cosmetics (INCI listed)

  • US

    Available OTC in cosmetic products (not a drug)

  • Worldwide

    Regulated as cosmetic ingredient, not pharmaceutical

Regulatory timeline(9)

  1. ~2005-2008
    DSM (now dsm-firmenich) develops SYN-TACKS peptide complex containing Palmitoyl Dipeptide-5 and Palmitoyl Dipeptide-6 for cosmetic use
  2. 2010
    Byrne et al. publish study on triple peptide complex stimulating collagen IV at DEJ, validating the scientific rationale for DEJ-targeting peptides (PMID 20618556)
  3. 2012-08
    CIR (Cosmetic Ingredient Review) announces Scientific Literature Review of 45 palmitoyl oligopeptides, including palmitoyl dipeptides
  4. 2013-03
    CIR tables the broad palmitoyl-oligopeptide assessment pending regrouping; no family-wide safety conclusion is issued.
  5. 2017
    Kim et al. publish clinical study on palmitoyl-KVK-L-ascorbic acid showing anti-wrinkle and depigmentation effects (PMID 28303328)
  6. 2019-12
    Jeong et al. publish study demonstrating peptide complexes stimulate DEJ basement membrane proteins and reduce wrinkles in vivo (PMID 31861912)
  7. 2020
    DSM publishes updated SYN-TACKS CB brochure with clinical data from 56-84 day evaluations
  8. 2022-12
    U.S. MoCRA (Modernization of Cosmetics Regulation Act) signed into law, enhancing FDA oversight of cosmetic ingredients including peptides
  9. 2025-12
    Xiong et al. publish study on Pal-KVK self-assembled nanostructures for sustained skincare delivery (PMID 41344485, J Control Release 2026)

Sources & FAQs

Research sources(11)

Frequently asked questions(5)

What is the difference between Palmitoyl Dipeptide-6 and Palmitoyl Dipeptide-5 in SYN-TACKS?

SYN-TACKS contains two peptides that work synergistically. Palmitoyl Dipeptide-6 Diaminohydroxybutyrate (Pal-Lys-Val-Dab-OH) is a tripeptide, while Palmitoyl Dipeptide-5 Diaminobutyroyl Hydroxythreonine (Pal-Lys-Val-Dab-Thr) is a tetrapeptide with an additional threonine residue. Together they target the dermal-epidermal junction proteins from complementary angles -- stimulating both hemidesmosomes and anchoring fibrils. The combination has been shown to be more effective than either peptide alone.

How does Palmitoyl Dipeptide-6 compare to Matrixyl (Palmitoyl Pentapeptide-4)?

Matrixyl (Pal-KTTKS) primarily stimulates collagen I and III synthesis in dermal fibroblasts, targeting the bulk of the dermis. Palmitoyl Dipeptide-6, in contrast, specifically targets the dermal-epidermal junction (DEJ), stimulating collagen IV, VII, XVII, laminin V, and integrin -- the anchoring proteins that connect epidermis to dermis. They address different aspects of skin aging and can be complementary when used together in formulations.

Is Palmitoyl Dipeptide-6 safe for sensitive skin?

Ingredient-specific safety data are limited. The EWG Skin Deep database rates it 1 out of 10 (lowest hazard). The cited CIR review does not establish this ingredient's safety, including its irritation or sensitization profile. As with any cosmetic ingredient, patch testing is recommended for individuals with very sensitive or reactive skin.

At what concentration is Palmitoyl Dipeptide-6 effective?

The manufacturer (DSM/dsm-firmenich) recommends using SYN-TACKS at up to 1% (v/v) in finished cosmetic formulations. Clinical evaluations by DSM tested the ingredient at 1% concentration over 56-84 days and reported improvements in skin firmness and wrinkle reduction. The pure peptide is present at a much lower concentration within the SYN-TACKS trade material, which also contains glycerin as a carrier.

How long does it take to see results from Palmitoyl Dipeptide-6?

Based on available clinical data, initial improvements in skin firmness and fine lines may be noticeable within 2-4 weeks of consistent twice-daily application. DSM's clinical evaluations assessed results at 56 days (8 weeks) and 84 days (12 weeks) for full benefit. A related study on DEJ-targeting peptides (PMID 31861912) showed significant wrinkle improvement after just 2 weeks.